TargetMol

Levosimendan

Product Code:
 
TAR-T2530
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2530-25mg25mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2530-50mg50mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2530-100mg100mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2530-200mg200mg£153.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2530-500mg500mg£261.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Levosimendan is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner.
CAS:
141505-33-1
Formula:
C14H12N6O
Molecular Weight:
280.291
Pathway:
Membrane transporter/Ion channel; Autophagy; Metabolism
Purity:
0.9991
SMILES:
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1
Target:
Potassium Channel; PDE; Carbonic Anhydrase; Autophagy

References

1. Haikala H, J Mol Cell Cardiol, 1995, 27(9), 1859-1866. 2. Yokoshiki H, Eur J Pharmacol, 1997, 333(2-3), 249-259. 3. Hasenfuss G, Circulation, 1998, 98(20), 2141-2147. 4. Slawsky MT, Circulation, 2000, 102(18), 2222-2227. 5. Edes I, Circ Res, 1995, 77(1), 107-113.